<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206613">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398801</url>
  </required_header>
  <id_info>
    <org_study_id>IND - DK74008</org_study_id>
    <nct_id>NCT00398801</nct_id>
  </id_info>
  <brief_title>Gastroparesis Registry</brief_title>
  <acronym>GpR</acronym>
  <official_title>Gastroparesis Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Gastroparesis Registry (GpR) is an observational study to clarify the epidemiology,
      natural history, clinical course, and other outcomes of gastroparesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Gastroparesis Registry (GpR) is an observational study to clarify the epidemiology,
      natural history, clinical course, and other outcomes of gastroparesis. The Gastroparesis
      Registry will also provide a resource to inform the development of clinical trials and
      ancillary studies of the epidemiology, etiology, pathophysiology, and impact of
      gastroparesis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">591</enrollment>
  <condition>Gastroparesis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Tertiary care centers for patients with symptoms of gastroparesis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms of gastroparesis of at least 12 weeks duration (do not have to be
             contiguous) with varying degrees of nausea, vomiting, abdominal pain, early satiety,
             post-prandial fullness,

          -  Completion of a 4-hour scintigraphic low fat Egg Beaters gastric emptying study

          -  Patients with either or both abnormal 2 hour (&gt;60% retention) and 4 hour (&gt;10%
             retention) gastric emptying will be enrolled and classified as definite gastroparesis
             (Gp)

          -  Patients with normal gastric emptying, but with symptoms of gastroparesis may be
             enrolled and classified as possible gastroparesis or gastroparesis-like with normal
             gastric emptying (GLNGE)

          -  Age at least 18 years at initial screening visit

          -  Ability and willingness to participate in follow-up

        Exclusion Criteria:

          -  Inability to comply with or complete the gastric emptying scintigraphy

          -  Presence of other conditions that could explain the patient's symptoms:

          -  Pyloric or intestinal obstruction

          -  Active inflammatory bowel disease

          -  Eosinophilic gastroenteritis

          -  Neurological conditions such as increased intracranial pressure, space occupying or
             inflammatory/infectious lesions

          -  Acute liver failure

          -  Advanced liver disease (Child's B or C)

          -  Acute renal failure

          -  Untreated chronic renal failure (serum creatinine &gt;3 mg/dL)

          -  Total or subtotal gastric resection (patients with prior fundoplication or
             postvagotomy gastroparesis after pyloroplasty or antrectomy with Billroth I, Billroth
             II, or Roux-en-Y gastrojejunostomy will be eligible for enrollment)

          -  Any other plausible structural or metabolic cause

          -  Any other condition, which in the opinion of the investigator would interfere with
             study requirements

          -  Inability to obtain informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Tonascia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry P Parkman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William L Hasler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas L Abell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pankaj J Pasricha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth L Koch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard W McCallum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University Health Science Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center (TTUHSC)</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www2.niddk.nih.gov/</url>
    <description>National Institute of Diabetes and Digestive and Kidney Diseases</description>
  </link>
  <link>
    <url>https://jhuccs1.us/gpcrc/</url>
    <description>Gastroparesis Clinical Research Consortium</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 16, 2014</lastchanged_date>
  <firstreceived_date>November 13, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastroparesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
